Tags

Type your tag names separated by a space and hit enter

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.
Diagn Microbiol Infect Dis. 2020 Sep; 98(1):115101.DM

Abstract

Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. Ceftolozane-tazobactam has been approved for treatment of complicated urinary tract infections and acute pyelonephritis, for complicated intra-abdominal infections (with metronidazole) in adults, and for hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia. This study analyzed gram-negative pathogen susceptibility in US and European patients who are considered at risk for infections caused by pathogens resistant to commonly used antimicrobials: patients in the intensive care unit (ICU), patients on the hematology/oncology or transplant service who may be immunocompromised, and patients >65 years old (yo). ICU patients had the lowest susceptibility for Enterobacterales and PSA. The susceptibility for isolates from the immunocompromised and >65 yo groups was similar. Ceftolozane-tazobactam was the most active agent against PSA, with ≥90%S for >65 yo and immunocompromised, and >80%S for ICU. Meropenem and ceftolozane-tazobactam were the most active agents against Enterobacterales.

Authors+Show Affiliations

JMI Laboratories, North Liberty, Iowa, USA; University of Iowa College of Medicine, Iowa City, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA. Electronic address: dee-shortridge@jmilabs.com.JMI Laboratories, North Liberty, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32622289

Citation

Pfaller, Michael A., et al. "Activity of Ceftolozane-tazobactam and Comparators when Tested Against Bacterial Surveillance Isolates Collected From Patients at Risk of Infections Caused By Resistant Gram-negative Pathogens." Diagnostic Microbiology and Infectious Disease, vol. 98, no. 1, 2020, p. 115101.
Pfaller MA, Shortridge D, Arends SJR, et al. Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. Diagn Microbiol Infect Dis. 2020;98(1):115101.
Pfaller, M. A., Shortridge, D., Arends, S. J. R., Duncan, L. R., Streit, J. M., & Flamm, R. K. (2020). Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. Diagnostic Microbiology and Infectious Disease, 98(1), 115101. https://doi.org/10.1016/j.diagmicrobio.2020.115101
Pfaller MA, et al. Activity of Ceftolozane-tazobactam and Comparators when Tested Against Bacterial Surveillance Isolates Collected From Patients at Risk of Infections Caused By Resistant Gram-negative Pathogens. Diagn Microbiol Infect Dis. 2020;98(1):115101. PubMed PMID: 32622289.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. AU - Pfaller,Michael A, AU - Shortridge,Dee, AU - Arends,S J Ryan, AU - Duncan,Leonard R, AU - Streit,Jennifer M, AU - Flamm,Robert K, Y1 - 2020/06/06/ PY - 2019/12/17/received PY - 2020/04/03/revised PY - 2020/05/30/accepted PY - 2020/7/6/pubmed PY - 2020/7/6/medline PY - 2020/7/5/entrez KW - Ceftolozane-tazobactam KW - Pseudomonas KW - Surveillance SP - 115101 EP - 115101 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 98 IS - 1 N2 - Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. Ceftolozane-tazobactam has been approved for treatment of complicated urinary tract infections and acute pyelonephritis, for complicated intra-abdominal infections (with metronidazole) in adults, and for hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia. This study analyzed gram-negative pathogen susceptibility in US and European patients who are considered at risk for infections caused by pathogens resistant to commonly used antimicrobials: patients in the intensive care unit (ICU), patients on the hematology/oncology or transplant service who may be immunocompromised, and patients >65 years old (yo). ICU patients had the lowest susceptibility for Enterobacterales and PSA. The susceptibility for isolates from the immunocompromised and >65 yo groups was similar. Ceftolozane-tazobactam was the most active agent against PSA, with ≥90%S for >65 yo and immunocompromised, and >80%S for ICU. Meropenem and ceftolozane-tazobactam were the most active agents against Enterobacterales. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/32622289/Activity_of_ceftolozane-tazobactam_and_comparators_when_tested_against_bacterial_surveillance_isolates_collected_from_patients_at_risk_of_infections_caused_by_resistant_gram-negative_pathogens L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(20)30478-8 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.